Fbw7 is a ubiquitin-ligase that targets several oncoproteins for proteolysis, but the full range of Fbw7 substrates is not known. Here we show that by performing quantitative proteomics combined with degron motif searches, we effectively screened for a more complete set of Fbw7 targets. We identify 89 putative Fbw7 substrates, including several disease-associated proteins. The transcription factor nF-κB2 (p100/p52) is one of the candidate Fbw7 substrates. We show that Fbw7 interacts with p100 via a conserved degron and that it promotes degradation of p100 in a GsK3β phosphorylation-dependent manner. Fbw7 inactivation increases p100 levels, which in the presence of nF-κB pathway stimuli, leads to increased p52 levels and activity. Accordingly, the apoptotic threshold can be increased by loss of Fbw7 in a p100-dependent manner. In conclusion, Fbw7-mediated destruction of p100 is a regulatory component restricting the response to nF-κB2 pathway stimulation.
F bw7 is the substrate recognition component of the Skp1-Cul1-F-box (SCF) ubiquitin-ligase SCF Fbw7 (ref. 1) . SCF Fbw7 acts as a central node by targeting several oncogenic regulators of proliferation, growth and apoptosis for proteasomal degradation. These include cyclin E 2 , c-Myc 3 , Notch 4 and Mcl1 (ref. 5 ). Deletion of the FBW7 gene results in developmental defects, embryonic lethality 3, 6 and genetic instability 7 and inactivation of FBW7 by loss of expression or mutation 8 has been firmly associated with tumour development 1, 9 . However, a detailed understanding of the full set of Fbw7 substrates, how regulation of its various substrates is coordinated, and how Fbw7 inactivation causes disease is still lacking. Fbw7 binds to substrates through interaction between its WD40 repeats 10 and a degron motif in the substrate. This binding commonly requires phosphorylation of the substrate's degron on the serine (S) or threonine (T) residues by Glycogen synthase kinase 3 (GSK3) 11 . The occurrence of multiple degrons in Fbw7 substrates has been suggested to increase their affinity to Fbw7 or make the interaction more likely to occur 10, 12, 13 .
NF-κB2 belongs to the NF-κB family of transcription factors that regulate the expression of several hundred genes and thereby the response to various stimuli such as cytokines and stress 14 . The NF-κB pathway is implicated in numerous diseases, in particular cancer and immune disorders, and is extensively explored as a therapeutic target. The NF-κB protein family also includes RelA, RelB, c-Rel and NF-κB1 (p105/p50). These proteins regulate transcription by complex formation, commonly RelA:p50 dimers, referred to as the canonical and RelB:p52 dimers referred to as the non-canonical NF-κB pathway 15 . The p100 protein has a dual role in transcription as the precursor of p52 and an I-κB-like inhibitor 16 . Although initially described as distinct pathways, the canonical and the non-canonical NF-κB pathways are now shown to share components and to be regulated in an integrated manner 17 .
To screen for a more complete set of Fbw7 substrates, we performed quantitative proteomics using FBW7 knockout (KO) cells, combined with bioinformatic analysis of degron motifs. We identified 89 putative Fbw7 substrates, including several diseaseassociated fundamental regulators of cell fate. Here we found NF-κB2 as one of the candidate Fbw7 substrates and show that Fbw7 ubiquitylates p100 and promotes its degradation in a GSK3β-dependent manner. Fbw7 inactivation causes elevated p100 levels, which in the presence of NF-κB pathway stimuli leads to increased p52 activity. We also show that the apoptotic threshold can be increased by loss of Fbw7 in a p100-dependent manner. This study provides insights into how inactivation of Fbw7 and constitutive activation of the NF-κB pathway might contribute to tumorigenesis.
Results
Quantitative proteomics. Several of the previously identified SCF Fbw7 targets have elevated protein levels in the human colorectal cancer cell-line HCT116 with homozygous deletion of the FBW7 gene, compared with its wild-type (WT) counterpart. To systematically identify candidate SCF Fbw7 substrates, we performed quantitative proteomics comparing HCT116 FBW7 WT and FBW7 KO cells. A schematic representation of the experimental design is outlined in Fig. 1a . Cytosolic and nuclear/organelle-enriched fractions from biological replicates of each cell type were subjected to isobaric labelling, using Tandem mass tags (TMT) 18 and the relative protein levels were determined by mass spectrometry (MS). More than 7,000 proteins were identified and quantified using peptide HiRIEF (high-resolution isoelectric focussing) LC-MS/MS (liquid chromatography tandem mass spectrometry) ( Supplementary Table S1 ). Approximately 1,700 unique proteins were found at significantly different levels in KO cells, including the known Fbw7 substrates Cyclin E, mTOR, KLF5, c-Myc and TGIF 2,19-21 , which, as expected, were upregulated in KO cells. Using Ingenuity pathway analysis, several pathways associated with the differentially expressed proteins were identified, including those related to known Fbw7 substrates such as c-Myc and mTOR ( Supplementary Table S2 ).
Fbw7 degron motif analysis. To filter out non-substrates from the pool of upregulated proteins, we combined the proteomic data with searches for proteins with the Fbw7 degron motif. Based on earlier studies of the cyclin E degrons 10 and analysis of the hydrophobicity and isoelectric point of the amino acids surrounding characterized degrons ( Supplementary Fig. S1 ), searches were made for the sequence 〈RK〉S/TP〈RK〉XS/T/E/D, where X is any amino acid and 〈RK〉 is any amino acid except arginine (R) or lysine (K) 11 . Distribution of this motif and variations was analysed proteome-wide and in the different protein pools identified in the proteomics experiment. Proteins with the motif were significantly enriched in the pool of upregulated and depleted in the pool of downregulated nuclear/organelle proteins. The cytoplasmic pools showed no significant enrichment for proteins with Fbw7 motifs ( Supplementary  Fig. S2a ). Most of the known SCF Fbw7 substrates contain multiple degron motifs ( Supplementary Table S3 ).
Interestingly, the relative size of the fraction of proteins with a given minimum number of motifs grows as that number increases, for known substrates compared with the proteome, suggesting that proteins with multiple motifs are more likely to be substrates (Supplementary Fig. S2b ). We therefore examined the occurrence of multiple Fbw7 degron motifs as well. To account for phosphorylation of degrons, we used Netphos 22 to predict phosphorylation sites in the motifs. Based on these analyses, 89 putative substrates were selected (Supplementary Data 1). The selection process is further explained in Supplementary Fig. S2c and summarized in Fig. 1b . All established Fbw7 substrates determined to be significantly changed by the proteomics analysis passed the selection process supporting the reliability of this strategy for discovery of Fbw7 substrates (Supplementary Data 1). The list of candidate substrates includes oncoproteins such as EGFR and RhoGEF-2. In addition, proteins with functions not previously associated with SCF Fbw7 substrates, like phosphatases and structural proteins were found ( Supplementary  Fig. S3 ). A total of 16 proteins were analysed by western blot (WB) to confirm the MS-based quantification data showing higher endogenous protein levels in FBW7 KO cells ( Fig. 1c ). Moreover, five candidates were tested by analysing their levels on ectopic expression of Fbw7 or Fbw7 together with active GSK3β, in the KO cells. As would be expected for substrates, restoring Fbw7 expression decreased the steady-state levels of these proteins ( Fig. 1d ).
NF-B2 ubiquitylation and levels are regulated by Fbw7. One of the more interesting novel SCF Fbw7 substrates was the Nuclear Factor of κB2 (NF-κB2), also named p100/p52. RelB was also identified as a potential Fbw7 substrate in the proteomic screen and as shown in Fig. 1c , both p100 and RelB were elevated in HCT116 FBW7 KO cells compared with the WT cells. Analysis of p100 and RelB protein half-life following inhibition of protein synthesis by cycloheximide treatment showed reduced turnover rate of both proteins in the KO cells ( Fig. 2a and b ).
In this study, we focus on p100 and its potential regulation by Fbw7. Real-time quantitative (qRT) PCR analysis showed a small decrease in p100 mRNA expression in the KO cells, further indicating that higher protein levels are not caused by higher mRNA transcription ( Fig. 2c ). Silencing Fbw7 in WT cells by small interfering RNA (siRNA) confirmed increased p100 protein, but not mRNA levels ( Fig. 2d-e ). We examined the turnover rate of p100 and p52 in Fbw7-silenced HEK293 cells. As shown in Fig. 2f , the half-life of p100 was prolonged in Fbw7-depleted cells. The very low levels of the basally processed p52 protein in these unstimulated cells were essentially unchanged. The levels of the other NF-κB family proteins that were also examined in HCT116 FBW7 WT and KO cells by WB analysis were unaffected ( Supplementary Fig. S4 ).
To directly test whether p100 is a ubiquitylation target of Fbw7, we performed in-vivo ubiquitylation assay. HCT116 FBW7 WT and Fbw7 KO cells were transfected with hemagglutinin (HA)-tagged ubiquitin. Immunoprecipitation (IP) of endogenous p100, followed by WB analysis for HA-ubiquitin, showed that poly-ubiquitylation of NF-κB2/p100 was inefficient in KO cells ( Fig. 2g ). Accordingly, NF-κB2 poly-ubiquitylation could be restored by transient Fbw7 expression in the KO cells ( Fig. 2h ).
Fbw7 interacts with NF-κB2 through a conserved degron.
Next, we examined the binding of NF-κB2 to Fbw7 using coimmunoprecipitation analysis. HEK293 cells were transfected with either full-length or F-box deleted (∆F) Fbw7. Fbw7∆F can bind to substrates, but not to the SCF core ligase and, therefore, has dominant negative properties 2 . Both WT and ∆F Fbw7 co-purified with immunoprecipitated endogenous NF-κB2/p100 ( Fig. 3a) . Similarly, reciprocal immunoprecipitations showed that NF-κB2 co-purified with GST-tagged Fbw7 (Fig. 3b ). To map the region in NF-κB2/p100 required for interaction with Fbw7, we used a series of carboxyterminally truncated NF-κB2 mutants ( Fig. 3c ). Cells were cotransfected with GST-Fbw7∆F and the indicated NF-κB2 deletion constructs. The 1-859 and 1-735 mutants both bound to Fbw7, but a larger deletion extending to amino acid 665, did not. This indicates that the integrity of the region 665-735 is essential for efficient interaction with Fbw7. The 1-665 mutant lacks a highly conserved Fbw7 degron motif at amino acid 705-711( Fig. 3d ). Accordingly, no interaction between Fbw7 and the 1-445 deletion, corresponding to p52, could be detected ( Fig. 3e ). We also tested the effect of ectopic Fbw7∆F expression on the steady-state levels of the different NF-κB2 deletion mutants. As anticipated, the levels of the 1-859 and 1-735, but not the 1-665 mutant increased on expression of Fbw7∆F ( Fig. 3f ). As Fbw7 substrate recognition and subsequent degradation depends on prior phosphorylation of the degron, we examined the turnover rate of an NF-κB2/p100 mutant in which the serines in the predicted GSK3 phosphorylation sites, S707 and S711, were replaced by alanines (p100-SA). As shown in Fig. 3g , the p100-SA mutant had a markedly increased half-life as compared with WT p100. To address how phosphorylation by GSK3β affects Fbw7-mediated regulation of p100, we compared p100 levels in FBW7 WT and KO cells following GSK3β inhibition or activation. In WT cells, treatment with the pharmacological GSK3β-inhibitor BIO increased the levels of p100, whereas ectopic expression of active GSK3β together with Fbw7 reduced p100 levels efficiently (Fig. 3h ). In contrast, no increase in p100 levels after GSK3β inhibition was detected in the KO cells, indicating that Fbw7-dependent modulation of p100 takes place following phosphorylation by GSK3β.
Fbw7 modulates p100/p52 levels and activity. To examine whether
Fbw7-mediated ubiquitylation of p100 also affects its partial degradation to p52, p100 processing was induced by expression of the NF-κB inducing kinase (NIK), a direct activator of the non-canonical NF-κB pathway 23 . p52 production was not perturbed in response to NIK stimulation in Fbw7-silenced HEK cells, indicating that in contrast to the SCF ubiquitin-ligase βTrCP, ubiquitination by Fbw7 is not required for p100 processing (Fig. 4a ). Interestingly, p52 protein levels were higher in Fbw7-depleted cells following stimulation by NIK. Similarly, we observed higher p52 levels on NIK stimulation of cells expressing the dominant-negative Fbw7∆F in all replicates, whereas cells expressing WT Fbw7 showed a concomitant decrease of both p100 and p52 proteins (Fig. 4b ). In addition, on stimulation of the non-canonical pathway by CD40 Ligand (CD40L) in MDA-231 cells ectopically expressing Fbw7, p52 levels were lower, suggesting that the steady-state level of the precursor p100 is reduced by Fbw7 and is rate-limiting for inducible p52 production in response to stimulation of the CD40 receptor as well ( Fig. 4c ). Knockdown of either Fbw7 or βTrCP caused accumulation of p100 in unstimulated cells. Following NIK-stimulation of βTrCPsilenced cells, p100 remains predominantly unprocessed in the cytoplasm but in Fbw7-silenced cells, p100 is processed and p52 translocated to the nucleus (Fig. 4d) . Notably, ectopic expression of Fbw7 in cells accumulating p100 as a result of processing block by βTrCP knockdown leads to a decrease in the levels of unprocessed, cytoplasmic p100 (Fig. 4e ). We also investigated the production of p52 on stimulation of cells with TNF-α, which is primarily an activator of the canonical pathway. Unlike NIK that directly induces processing of p100 to p52, TNF-α stimulation contributes indirectly to increased p52 levels, likely through inducing p100 transcription, as p100 is a transcriptional target of the canonical NF-κB pathway 24, 25 . TNF-α treatment further enhanced p52 levels in KO compared with WT cells. IP of the endogenous p52 with anti-RelB antibodies showed that p52:RelB complexes are more abundant in basal and in TNF-α stimulated FBW7-KO cells (Fig. 4f ). This is interesting as complex formation between p52 and RelB is a prerequisite for transcriptional activation of a subset of p52 targets 15 .
To investigate the effect of Fbw7-mediated control of p100 on the non-canonical NF-κB pathway activity, we performed transcription assays. Consistent with the increased abundance of p52:RelB complexes in stimulated FBW7 KO cells, expression of p52-specific targets Cyclin D1, Bcl2 and Skp2 was higher in these cells, as shown by qPCR analysis of relative messenger RNA levels (Fig. 4g ). In support of the inhibitory role of p100 on NF-κB activity 26 , we observed that in unstimulated HCT FBW7 KO cells with higher p100 levels, basal NF-κB activity was lower when compared with WT cells (Fig. 5a ). Also, overexpression of p100 or the p100SA mutant suppressed κB-TATA reporter activity in unstimulated HEK and HCT cells (Fig. 5b) . However, on stimulation of cells by NIK, κB-TATA promoter activity was recovered. NIK-and prolonged TNF-α-stimulated HCT cells showed a higher fold-induction of the relative κB-TATA activity in FBW7 KO compared with WT cells (Fig. 5c ). This indicates that induction of processing in cells with elevated p100 levels can lead to a greater response to stimulation. Gene-specific luciferase assay in U2OS cells, which have constitutively active p100 processing 15 , demonstrated that expression of Fbw7∆F increases cyclin D1 promoter activity (Fig. 5d) . Similarly, stimulated Fbw7∆F-expressing HEK cells showed an enhanced κB-TATA activity (Fig. 5e ). Moreover, we detected increased protein levels of Cyclin D1, Bcl-2 and Skp2 following TNF-α stimulation in FBW7 KO cells (Fig. 5f ).
Elevated p100 on Fbw7 loss is pro-survival when processed.
To assess the consequence of Fbw7-mediated control of p100 on cell fate, we performed viability and apoptosis analysis. Deregulation of the NF-κB2 pathway has been shown to be essential for cell survival by controlling the expression of anti-apoptotic genes, for example, in lymphomas 27 . However, unprocessed p100 has also been reported to induce apoptosis through non-transcriptional as well as transcriptional processes 28, 29 . Cell survival in response to treatment with the anticancer drugs Daunorubicin, Doxorubicin and Etoposide, known to be affected by the NF-κB pathway, was analysed 30, 31 . We show that in U2OS cells, that have constitutive p100 processing, knockdown of Fbw7 decreased sensitivity to Daunorubicin and Etoposide treatment and knockdown of p100 reversed the prosurvival effect resulting from Fbw7 loss (Fig. 6a-c by Fbw7, reduced apoptosis in response to Doxorubicin in NIKstimulated HEK293 cells (Fig. 6d) . Together, these data support a pro-survival effect of p100 deregulation as a result of Fbw7 loss in cells with activated p100 processing.
Consistent with a role for p52 in tumorigenesis, we found elevated protein levels of p100/p52 in several primary paediatric B-cell Acute lymphoblastic leukaemia (B-ALL) ( Supplementary Fig. S5 ). To investigate a potential relationship between Fbw7 and NF-κB2 in B-ALL, we performed correlation analysis for the expression of Fbw7 and specific NF-κB2 target genes in two independent cohorts of 178 and 297 patients. Considering expression as a continuous variable, a highly significant inverse association was found between the expression of Fbw7 and several NF-κB2 target genes, such as Bcl2 and Bcl2L1 ( Supplementary Table S4 ).
Discussion
Quantitative proteomics analysis is a logical choice for E3-ligase target studies. However, high analytical depth is essential for successful identification of target proteins. Here we used HiRIEF LC-MS/MS to quantify over 7,000 proteins. A combination of conservative bioinformatic criteria was then applied to separate primary and downstream effects with minimal loss of information. By this method, we identify NF-κB2 as a novel Fbw7 target.
Our data suggests that a pool of p100 is constitutively phosphorylated by GSK3β, ubiquitinated by Fbw7 and degraded independently of stimulation of the NF-κB pathway. Although inhibition of either Fbw7 or βTrCP leads to increased p100 levels, the distribution pattern of p100 and p52 protein is clearly distinct in stimulated cells, under each condition. Stimulation of Fbw7-deficient cells leads to increased p52 levels consistent with the higher expression of p52-specific targets in these cells.
Based on our findings, we present a model for how Fbw7 modulates the NF-κB pathway activity in normal and diseased cells (Fig. 7) . Normally, p100 is the prevalent form of NF-κB2 and processing to p52 is restricted 16 , but in response to stimulation, p100 processing is transiently triggered in a NIK-and βTrCP-dependent manner 16, 32 . Our results suggest that the control of p100 levels by Fbw7-mediated ubiquitylation and proteolysis is decisive for the extent of the transcriptional response on stimulation, as Fbw7-deficient cells with elevated p100 levels have increased p52 activity leading to increased cell survival. This is intriguing since inactivation of Fbw7 and/or activation of NF-κB2 (p52) is a frequent event in various tumour types, including haematological malignancies [33] [34] [35] . The inverse correlation between expression of Fbw7 and specific NF-κB2 target genes that we found in ALL underscores the link between Fbw7 and NF-κB2 in tumorigenesis. Moreover, considering the interconnected nature of the NF-κB network of transcription regulators 36 , we suggest that control of p100 levels by Fbw7 is likely to be a general modulator of response to stimulation of both the NF-κB pathways.
During the final stages of the preparation of this manuscript, we became aware of another study demonstrating that efficient activation of the non-canonical NF-κB pathways is dependent on the elimination of a nuclear pool of p100 through either degradation by Fbw7 or export to cytoplasm 28 . This study also shows that in multiple myeloma cell lines, accumulation of unprocessed p100 is pro-apoptotic. There is previous evidence for both a pro-and anti-apoptotic role of p100 under distinct conditions 27, 29 . While unprocessed p100 has been shown to be primarily pro-apoptotic, we show that elevated p100, when processed to p52 is pro-survival. Thus, the outcome of Fbw7-mediated modulation of p100 levels on cell survival is different under distinct modes of NF-κB pathway activation. Unlike in multiple myeloma cell lines, in many other cancer types Fbw7 is inactivated, consistent with a pro-survival role for deregulated p100 as a result of Fbw7 deficiency.
In the present study we provide a novel technique for systematic discovery of SCF Fbw7 ubiquitin-ligase substrates that could readily be adapted for other ubiquitin-ligases. The identified candidates are proteins with greater functional diversity than previously anticipated for Fbw7 substrates, and further studies of these targets would provide a more complete understanding of Fbw7 function and how its deregulation causes disease. In cancer, the NF-κB signalling is often dysregulated and constitutively activated 37 . Through study of p100 regulation by Fbw7, we provide insights into how inactivation of Fbw7 together with constitutive activation of the NF-κB pathway might contribute to tumorigenesis.
Note added in proof: Similar findings have been reported while this work was under consideration (Fukushima et al. Cell Rep. 1, 434-443, 2012. SCFFbw7 modulates the NFκB signaling pathway by targeting NFκB2 for ubiquitination and destruction).
Methods
Cell culture and transfections. Human embryonic kidney HEK293 and human osteosarcoma U2OS cell lines were cultured in DMEM (Invitrogen). Human colorectal carcinoma cell lines HCT116 FBW7 + / + (WT) and HCT116 FBW7 − / − (KO) were cultured in McCoy's medium (Invitrogen). All cells were supplemented with 10% fetal calf serum at 37 °C in 5% CO 2 . Cells were treated with the proteasome inhibitor MG132 (Sigma) at 40 µM, Cycloheximide (Sigma) at 100 µg ml − 1 , TNF-α (Prepotech) at 5-10 ng ml − 1 , GSK3β inhibitor Bromoindirubin (Sigma) at 5 µM for 3 h. Soluble hexa-meric CD40 ligand (ENZO Life Science) was used 0.4 µg ml − 1 , over night. FBW7 plasmids and transfections were performed as previously described 8, 38 using TransIT-LT1 (Mirus) reagent or GeneJuice Transfection Reagent (Novagen). Transfection of siRNA oligonucleotides was performed with HiPerfect transfection reagent (Qiagen) for 48 h. Fbw7 siRNA has been described previously 38 . βTrCP siRNA was a kind gift from Dr. Guardavaccaro. Full-length and C-terminal deletion NF-κB2 deletion constructs and NIK vectors were described previously 23 . GSK3β plasmid was a kind gift from Dr. Theresa Vincent. The double-point mutant of p100, where serine 707 and serine 711 was replaced by alanines (p100-SA), was generated using the Quickchange kit, according to the manufacturer's instructions (Stratagene).
Immunoprecipitation and immunoblotting.
Nuclear-and cytosolic-enriched fractions were prepared as described previously 14 . Whole-cell lysate preparation, immunoprecipitation and immunoblotting have been described previously 38, 39 . Antibodies: anti-NF-κB2 (Santa Cruz) (2 µg ml − 1 ) and (Sigma) (1 µg ml − 1 ), anti cyclin E (Santa Cruz) 0.4 µg ml − 1 , anti-HA (Santa Cruz) 1 µg ml − 1 , anti-β-actin (Sigma) (1:5,000), anti-FLAG M2 (Sigma) (1:1,000). Antibodies to Bcl-2 (1:1,000), Cyclin D1 (1:1,000), Skp2 (1:1,000) were obtained from Cell Signaling Technology. Antibodies to RhoGEF2 (2 µg ml − 1 ), EGFR (0.2 µg ml − 1 ), UBE4B (0.05 µg ml − 1 ), ERN1 (2 µg ml − 1 ), TMF1 (0.5 µg ml − 1 ), SUPT5 H (0.4 µg ml − 1 ), WD12 (0.2 µg ml − 1 ), TEP1 (0.1 µg ml − 1 ), MAP7D3 (1 µg ml − 1 ), UHRF1BP1 (2 µg ml − 1 ), MORC-1 (0.4 µg ml − 1 ), UBAP2 (0.2 µg ml − 1 ) were from Human Protein Atlas antibodies. In-vivo ubiquitination assays were performed essentially as described previously 40 . Briefly, HCT116 (WT and KO) cells were transfected with a plasmid expressing HA-ubiquitin for 24 h and treated with MG132 (50 µM) for 6 h before collectinging and extraction in 1% SDS and 10 mM N-ethylmaleimide (Sigma). Protein extracts were sonicated, diluted ten times in RIPA buffer followed by immunoprecipitation of equal amounts of total NF-κB2 protein using anti-NF-κB2 antibodies.
Pathway analysis. The proteins identified by MS were studied for their biological function and pathways. Basic information about the proteins was retrieved from UniProt/SwissProt database (release 2011-06). These proteins were also analysed using ingenuity pathway analysis (IPA version 9, release date 2011-03-12).
Reporter assays and mRNA expression analysis. Luciferase reporter assays were carried out using the Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer's instructions. κB-responsive gene-specific reporters from the Cyclin D promoter 39 and the Bcl-2 promoter (a kind gift from Professor Neil Perkins) were used. κB-TATA luciferase reporter has been described previously 25 . Renilla was used for normalization. Luciferase reporter experiments were repeated three times. Total RNA was extracted using TRIzol reagent (Invitrogen) and reverse-transcribed into complementary DNA by using Superscript reverse transcriptase (Invitrogen) followed by quantitative RT-PCR (qRT-PCR) analysis, as described previously 41 . Gene expression levels were analysed on an ABI 7300 Real-Time PCR System (SDS software version 1.3.1) and normalized, based on GAPDH mRNA expression. Primer sequences are indicated in Supplementary Table S5 . For Bcl-2, Quantitate SYBR-validated primers were used (Qiagen). Gene-specific mRNA expression levels were determined by Affymetrix U133 plus 2.0 GeneChips, as previously described in ref. 42 . Relations between continuous variables were investigated by means of the Spearman's rank correlation coefficient test. A P-value of < 0.05 was considered to indicate statistical significance. In response to specific stimuli p100 is processed to p52 through nIK-mediated phosphorylation. Increase in p100 levels as a result of Fbw7 inactivation leads to elevated p52 production, alterations in p52/nF-κB complex formation and activity on stimulation. In the absence of stimuli, p100 binds to and inhibits various nF-κB complexes. Consequently, Fbw7-mediated regulation of p100 levels controls downstream transcriptional targets of both the canonical (RelA:p50) and the noncanonical (RelB:p52) nF-κB pathways.
